4月1日盘中，亚盛医药（股票代码：AAPG）股价大涨5.56%，引发市场广泛关注。这一强劲涨势背后，是公司近期发布的亮眼财报以及产品管线的重大进展。
根据亚盛医药最新发布的财报显示，公司2024年度收入达到9.8亿元，同比大幅增长342%。这一增长主要得益于其明星产品耐立克的强劲销售，以及来自武田制药的选择权款项。在当前生物医药行业整体处于低迷期的背景下，亚盛医药交出如此亮眼的成绩单实属难得，充分展现了公司的经营实力。
除了财务表现外，亚盛医药在产品管线方面也取得了重大突破。公司的核心产品耐立克已获FDA批准开展注册III期临床，为其国际化战略奠定了基础。同时，新型Bcl-2抑制剂APG-2575已提交上市申请，有望成为公司新的增长引擎。这些进展不仅展示了亚盛医药在研发领域的持续创新能力，也为公司未来的长期发展提供了有力支撑。市场普遍认为，随着这些产品的陆续获批和商业化，亚盛医药有望持续保持高速增长态势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.